Business Context and Reporting Period
Filing identity discrepancy: The supplied Form 10-Q is for Aileron Therapeutics, Inc. (Nasdaq: ALRN), not Rein Therapeutics, Inc. It covers the three months ended March 31, 2019 and was filed May 8, 2019.
Aileron is a clinical-stage biopharmaceutical company developing stabilized cell-permeating alpha-helical peptides. Its lead candidate, ALRN-6924, targets the p53-MDM2/MDMX pathway in oncology. No product candidate had received marketing approval or generated product revenue.
Key Financial Metrics
| Metric | Q1 2019 | Q1 2018 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $4.174 million | $4.846 million | Down $0.672 million |
| General and administrative expense | $3.139 million | $2.917 million | Up $0.222 million |
| Total operating expenses | $7.313 million | $7.763 million | Down $0.450 million |
| Net loss | $7.213 million | $7.588 million | Loss decreased $0.375 million |
| Basic and diluted loss per share | $0.49 loss | $0.52 loss | Improved |
| Cash used in operating activities | $7.501 million | $6.929 million | Use increased $0.572 million |
| Cash, cash equivalents and investments at period end | $13.270 million | Not clearly provided in the filing excerpt | Not comparable |
Because revenue was zero, gross and operating margins are not meaningful. Accumulated deficit was $175.979 million at March 31, 2019, compared with $168.493 million at December 31, 2018.
- Cash and cash equivalents were $11.272 million, investments were $1.998 million, and restricted cash totaled $0.593 million.
- Total assets were $22.399 million and stockholders’ equity was $12.847 million.
- Operating lease liabilities totaled approximately $5.316 million, including $0.387 million current and $4.929 million non-current.
- The prior $5.342 million construction financing liability was eliminated upon adoption of the new lease standard.
- Stock-based compensation expense was $0.563 million, compared with $0.767 million in Q1 2018.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined 14%, primarily due to lower ALRN-6924 and p53 program costs and lower employee, facility and other development costs.
- General and administrative expense increased 8%, driven principally by higher personnel and regulatory-compliance consulting costs.
- Net loss improved 5%, although operating cash burn increased because of working-capital movements and vendor payment timing.
- Investing activities provided $7.973 million, primarily from investment maturities or sales, compared with $2.400 million in Q1 2018.
- The company adopted ASC 842 on January 1, 2019, recognizing a $6.543 million operating lease right-of-use asset at March 31, 2019 and related lease liabilities.
- Common shares outstanding increased to 14.875 million at March 31, 2019 from 14.748 million at December 31, 2018, principally from stock-option exercises.
Guidance, Outlook, Risks and Unusual Items
- The company reported that its ALRN-6924 and palbociclib Phase 2a combination study was enrolling ahead of schedule, with 12 patients on study. It expected interim data on approximately 15 patients in late September or early October 2019.
- Management expected to begin enrollment in a Phase 1b/2 myelopreservation trial in small-cell lung cancer during the third quarter of 2019 and expected proof-of-concept data in the first half of 2020.
- The company ceased enrollment and further clinical development in PTCL, AML and MDS at that time, citing available resources, commercial opportunity assessments and changes in the competitive landscape.
- On April 2, 2019, after quarter-end, the company completed a private placement with approximately $26.0 million of gross proceeds, before approximately $1.7 million of placement-agent fees and other offering expenses. The financing included common stock, pre-funded warrants and five-year warrants exercisable at $2.00 per share.
- Management stated that March 31 cash, cash equivalents and investments together with the net private-placement proceeds were expected to fund operating expenses and capital expenditures into the fourth quarter of 2020. This estimate depends on assumptions that may prove incorrect, and additional capital will likely be required.
- The company had no revenue, continued to incur operating losses and had no committed external source of funding. It identified risks related to clinical-trial success, regulatory approval, patient enrollment, manufacturing, intellectual property, reliance on third parties, competition and future financing.
- A patient death from tumor lysis syndrome occurred in an earlier Phase 1 single-agent ALRN-6924 AML/MDS trial; the filing states that such events may affect perceptions of product safety.
- No material legal proceedings were reported. Management concluded that disclosure controls and procedures were effective as of March 31, 2019, and reported no material change in internal control over financial reporting.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the provided filing is for Aileron Therapeutics, Inc., whereas the request names Rein Therapeutics, Inc.
- Verify the April 2, 2019 private placement closing, net proceeds, registration rights, share issuance and potential dilution from pre-funded and common warrants.
- Assess whether the projected funding runway into the fourth quarter of 2020 remains adequate given clinical-trial costs, operating cash burn and the company’s stated need for additional financing.
- Review interim and subsequent clinical data for ALRN-6924, particularly the palbociclib combination study and the planned myelopreservation program.
- Evaluate the implications of discontinuing PTCL, AML and MDS development programs and the reported prior tumor lysis syndrome death.
- Reconcile the ASC 842 lease accounting adjustments and the remaining approximately $5.316 million of operating lease liabilities.
- Review the company’s patent licenses, milestone obligations, royalty terms and the disclosed historical dispute with Harvard concerning diligence obligations.